Redx Pharma Plc 0RX.F Stock
Redx Pharma Plc Price Chart
Redx Pharma Plc 0RX.F Financial and Trading Overview
| Redx Pharma Plc stock price | 0.08 EUR |
| Previous Close | 0.31 EUR |
| Open | 0.31 EUR |
| Bid | 0.31 EUR x N/A |
| Ask | 0.34 EUR x N/A |
| Day's Range | 0.31 - 0.31 EUR |
| 52 Week Range | 0.3 - 0.78 EUR |
| Volume | 150 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 107.61M EUR |
| Beta (5Y Monthly) | -0.218773 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0RX.F Valuation Measures
| Enterprise Value | 88.68M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.508414 |
| Price/Book (mrq) | 6.9333334 |
| Enterprise Value/Revenue | 7.011 |
| Enterprise Value/EBITDA | -3.343 |
Trading Information
Redx Pharma Plc Stock Price History
| Beta (5Y Monthly) | -0.218773 |
| 52-Week Change | -56.66% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.78 EUR |
| 52 Week Low | 0.3 EUR |
| 50-Day Moving Average | 0.33 EUR |
| 200-Day Moving Average | 0.53 EUR |
0RX.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 334.91M |
| Float | 37.56M |
| Short Ratio | N/A |
| % Held by Insiders | 16.81% |
| % Held by Institutions | 79.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | -229.34% |
| Operating Margin (ttm) | -212.93% |
| Gross Margin | 100.00% |
| EBITDA Margin | -209.70% |
Management Effectiveness
| Return on Assets (ttm) | -40.66% |
| Return on Equity (ttm) | -285.70% |
Income Statement
| Revenue (ttm) | 12.65M EUR |
| Revenue Per Share (ttm) | 0.04 EUR |
| Quarterly Revenue Growth (yoy) | -72.29% |
| Gross Profit (ttm) | 18.69M EUR |
| EBITDA | -26523000 EUR |
| Net Income Avi to Common (ttm) | -29008000 EUR |
| Diluted EPS (ttm) | -0.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.61M EUR |
| Total Cash Per Share (mrq) | 0.1 EUR |
| Total Debt (mrq) | 18.79M EUR |
| Total Debt/Equity (mrq) | 125.92 EUR |
| Current Ratio (mrq) | 1.524 |
| Book Value Per Share (mrq) | 0.045 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -29726000 EUR |
| Levered Free Cash Flow (ttm) | -20684000 EUR |
Profile of Redx Pharma Plc
| Country | Germany |
| State | N/A |
| City | Macclesfield |
| Address | Alderley Park |
| ZIP | SK10 4TG |
| Phone | 44 16 2546 9900 |
| Website | https://www.redxpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 95 |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Q&A For Redx Pharma Plc Stock
What is a current 0RX.F stock price?
Redx Pharma Plc 0RX.F stock price today per share is 0.08 EUR.
How to purchase Redx Pharma Plc stock?
You can buy 0RX.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Redx Pharma Plc?
The stock symbol or ticker of Redx Pharma Plc is 0RX.F.
Which industry does the Redx Pharma Plc company belong to?
The Redx Pharma Plc industry is Biotechnology.
How many shares does Redx Pharma Plc have in circulation?
The max supply of Redx Pharma Plc shares is 449.82M.
What is Redx Pharma Plc Price to Earnings Ratio (PE Ratio)?
Redx Pharma Plc PE Ratio is now.
What was Redx Pharma Plc earnings per share over the trailing 12 months (TTM)?
Redx Pharma Plc EPS is -0.12 EUR over the trailing 12 months.
Which sector does the Redx Pharma Plc company belong to?
The Redx Pharma Plc sector is Healthcare.